UK CBD product transparency benchmark 2026

Executive summary

• The sample contains 354 products from 24 brands across six CBD formats. It describes the thCBDx partner catalogue, not the whole UK market.
• Every eligible record had a current catalogue price, but only 80.8% exposed a parseable pack size and 44.6% a structured flavour field.
• Median unit cost varies dramatically by format: drinks are structurally unlike concentrated oils or vape liquids, so cross-format “cheapest CBD” rankings are usually misleading.
• Only 106 products had a full editorial review at snapshot time. Unreviewed rows remain in the dataset but carry no invented score.
• Retailers can improve comparability quickly by publishing total CBD, pack volume/count, complete ingredients, price-check dates and batch-specific documentation in consistent fields.

The observed catalogue

Oils and vape products dominate this particular sample. That is a property of partner coverage and eligibility rules—not a measure of UK consumer demand or market share.

Finding 1: unit cost needs a format boundary

The median observed price per 100mg ranges from £2.27 to £9.37. That spread is not evidence that one format is universally better value. Drinks include water, flavour and packaging; topicals use different bases; oils and vape liquids concentrate milligrams differently. Meaningful comparisons stay within format and report the middle 50%, not only one winner.

Finding 2: a visible price is not a complete label

Price coverage reached 100%, yet parseable pack-size coverage was 80.8%. A product can therefore appear commercially complete while still being hard to compare. Flavour coverage at 44.6% partly reflects genuinely unflavoured formats, but it also exposes inconsistent structured tagging.

The recommendation is not “add more marketing copy.” It is to put stable facts in stable fields: total CBD, volume or count, concentration, ingredients, spectrum wording, date checked and—where supplied—a batch identifier linked to a certificate.

Finding 3: reputation is not product evidence

Brand-level review platforms can inform customer-service context, but they cannot prove an exact product's contents. thCBDx therefore treats a current label, exact-product feedback and batch documentation as different evidence layers. A high brand rating is never copied into an individual product score.

Regulatory context

Pure isolated CBD is not itself controlled under UK drugs legislation, while THC and other controlled cannabinoids are; product status depends on composition and the applicable legal regime. The Home Office stresses that its factsheet is general guidance rather than legal advice. For ingestible CBD, the Food Standards Agency's food and novel-food guidance is the relevant starting point. Vape disposal is a separate environmental and product-safety issue: OPSS advises keeping used vapes out of general waste and household recycling and using retailer take-back or dedicated collection.

Home Office cannabinoid factsheet · FSA CBD business guidance · OPSS vape disposal guidance

Recommendations

Methodology and limitations

The analysis includes available, image-bearing products classified into six CBD categories with a positive extractable total-CBD value and sufficient publication signals. Prices are the lowest catalogue price and may represent a starting variant. Unit cost is price divided by total CBD, multiplied by 100. Medians and linearly interpolated quartiles are calculated within category.

The sample excludes products failing the publication threshold and brands outside current partner feeds. Extraction errors, variant structures and retailer changes remain possible. Findings do not establish legality, laboratory quality, safety, efficacy, consumer preference or market size. The downloadable rows make these limitations testable rather than hidden.